Bayer AG and Asklepios BioPharmaceutical (AskBio) have announced a new strategic collaboration with Belief BioMed (BBM) to explore the potential for new gene therapies. Under the terms of the contract, the companies will combine efforts and experience in gene therapy technology to explore potential therapies in diseases that may be treatable using a liver-targeted approach. […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!